{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:02:20Z","timestamp":1780369340102,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.biopha.2012.05.001","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T12:16:36Z","timestamp":1341231396000},"page":"323-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10"],"prefix":"10.1016","volume":"66","author":[{"given":"Luciano","family":"Mazzoccoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia H.","family":"Cadoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni W.","family":"Amarante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus V.N.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro V.","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique C.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.05.001_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0968-0896(01)00308-X","article-title":"Structural development of biological response modifiers based on thalidomide","volume":"10","author":"Hashimoto","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.biopha.2012.05.001_bib0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.2413547","article-title":"Tumor necrosis factor (TNF)","volume":"230","author":"Old","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.biopha.2012.05.001_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/524688","article-title":"Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy","volume":"197","author":"Bochud","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2012.05.001_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.biopha.2012.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0030","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopha.2012.05.001_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-4632.2004.02445.x","article-title":"Thalidomide for dermatology: a review of clinical uses and adverse effects","volume":"44","author":"Faver","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/08830180801911339","article-title":"Thalidomide: mechanisms of action","volume":"27","author":"Paravar","year":"2008","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0162-3109(98)00010-1","article-title":"Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells","volume":"40","author":"Rowland","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.biopha.2012.05.001_bib0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1183\/09031936.06.00131505","article-title":"Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease","volume":"28","author":"Ye","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.biopha.2012.05.001_bib0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1470-2045(06)70657-X","article-title":"Advances in oral therapy for multiple myeloma","volume":"7","author":"Morgan","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0060","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4049\/jimmunol.161.8.4236","article-title":"Cc-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production","volume":"161","author":"Marriott","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm000084m","article-title":"Terminally alkylated polyamine analogues as chemotherapeutic agents","volume":"44","author":"Casero","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopha.2012.05.001_bib0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1645\/GE-1153.1","article-title":"Transcriptional inhibition of interleukin-12 promoter activity in leishmania spp.-infected macrophages","volume":"94","author":"Jayakumar","year":"2008","journal-title":"J Parasitol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.biopha.2012.05.001_bib0080","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1016\/j.bmcl.2006.08.113","article-title":"Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators","volume":"16","author":"del Olmo","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.biopha.2012.05.001_bib0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1248\/cpb.55.223","article-title":"Thalidomide analogs from diamines: Synthesis and evaluation as inhibitors of TNF-alpha production","volume":"55","author":"de Almeida","year":"2007","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.biopha.2012.05.001_bib0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.micinf.2005.05.019","article-title":"Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of mycobacterium tuberculosis ESAT-6 and CFP-10 in brazilian tuberculosis patients","volume":"8","author":"Abramo","year":"2006","journal-title":"Microbes Infect"},{"key":"10.1016\/j.biopha.2012.05.001_bib0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.coph.2004.03.005","article-title":"Inhibition of IL-6 for the treatment of inflammatory diseases","volume":"4","author":"Nishimoto","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0100","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bmcl.2004.12.012","article-title":"Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide","volume":"15","author":"Machado","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.biopha.2012.05.001_bib0105","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1248\/cpb.54.1709","article-title":"Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity","volume":"54","author":"Nakamura","year":"2006","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.biopha.2012.05.001_bib0110","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2012.05.001_bib0115","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1016\/S0960-894X(03)00778-9","article-title":"Alpha-fluoro-substituted thalidomide analogues","volume":"13","author":"Man","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.biopha.2012.05.001_bib0120","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.biopha.2012.05.001_bib0125","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/jm9603328","article-title":"Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity","volume":"39","author":"Muller","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopha.2012.05.001_bib0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1016-8478(23)13028-7","article-title":"The effects of thalidomide on the stimulation of NF-kappab activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line","volume":"17","author":"Kim","year":"2004","journal-title":"Mol Cells"},{"key":"10.1016\/j.biopha.2012.05.001_bib0135","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mrna degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.biopha.2012.05.001_bib0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0753-3322(01)00147-0","article-title":"Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. Leprae-induced TNFalpha production in vitro","volume":"56","author":"Sampaio","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2012.05.001_bib0145","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active crohn's disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2012.05.001_bib0150","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2169\/internalmedicine.46.6278","article-title":"Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers","volume":"46","author":"Hata","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.biopha.2012.05.001_bib0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1212\/01.WNL.0000103239.72937.AD","article-title":"Peripheral blood leukocyte no production in MS patients with a benign vs progressive course","volume":"62","author":"Ramsaransing","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2012.05.001_bib0160","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and related cytokines and receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0165","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol Med"},{"key":"10.1016\/j.biopha.2012.05.001_bib0170","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.4049\/jimmunol.176.6.3321","article-title":"TGF-beta requires CTLA-4 early after T cell activation to induce foxp3 and generate adaptive CD4+CD25+regulatory cells","volume":"176","author":"Zheng","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0175","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.4049\/jimmunol.172.5.2778","article-title":"CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells","volume":"172","author":"Zheng","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0180","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.05.001_bib0185","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.leu.2404869","article-title":"The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide","volume":"22","author":"Giannopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2012.05.001_bib0190","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/01.tp.0000266892.69117.9a","article-title":"Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection","volume":"83","author":"Haskova","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.biopha.2012.05.001_bib0195","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2133.2007.08137.x","article-title":"The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets","volume":"157","author":"Wenzel","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0200","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.bjp.0704193","article-title":"Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat\u00a0\u2013\u00a0role of endothelial cell-leukocyte interaction","volume":"133","author":"Lienenluke","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0205","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0210","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2012.05.001_bib0215","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","article-title":"IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade","volume":"159","author":"Ogata","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.biopha.2012.05.001_bib0220","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/168.2.408","article-title":"The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum","volume":"168","author":"Sampaio","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2012.05.001_bib0225","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4269\/ajtmh.2005.72.518","article-title":"A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum","volume":"72","author":"Villahermosa","year":"2005","journal-title":"Am J Trop Med Hyg"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:49:13Z","timestamp":1760093353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0753332212000583"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.05.001","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}